OmanDocSign in

Curriculum · Metabolic and Endocrine and Diabetes Mellitus

Lipid targets in the patient with diabetes

What it is

Lipid-associated risk for CVD events is graded and continuous, so the LDL-C goal is set by the cardiovascular risk category the patient falls into, and diabetes is one of the things that moves a patient up that scale, alongside CKD stage 3, severe HTN and an LDL of 190 or above.

How it is treated

Target LDL cholesterol levels for adults with diabetes are <100 mg/dL (2.60 mmol/L), HDL cholesterol levels are >40 mg/dL (1.02 mmol/L), and triglyceride levels are <150 mg/dL (1.7 mmol/L). In women, who tend to have higher HDL cholesterol levels than men, an HDL goal 10 mg/dL higher may be appropriate. Two long red diagonal strokes are drawn by hand across the whole of that paragraph on the page, running on up to the risk-stratified table, and a red arrow is drawn by hand beside the High risk row of that table.

Read against the cardiovascular risk category, the target LDL-C is graded:

The two ways of putting it do not land on the same target for diabetes. The risk category places diabetes at high risk with an LDL-C target <70 mg/dL (<1.8 mmol/L), while the target LDL cholesterol for adults with diabetes is given as <100 mg/dL (2.60 mmol/L). One question in the material asks for the target level of LDL in a diabetic patient and gives <2.5; that answer is struck through by hand and corrected to <1.8. That follows the risk table, where diabetes by itself sits in the high risk row. The national guideline does not put every diabetic in that row, so the two split on the diabetic without overt CVD: <1.8 mmol/L by the risk table, and <2.6 mmol/l by the guideline, which keeps <1.8 mmol/l for overt CVD or diabetes with end organ damage. Both are written here as they stand.

The national guideline states the goal twice over, as a fall from baseline and as a level, and it sets two groups apart. In individuals without overt CVD the primary goal is a reduction in LDL cholesterol of about 30% from baseline with an LDL cholesterol below 2.6 mmol/l; in individuals with overt CVD, or diabetes with end organ damage, the goal is a reduction of about 50% from baseline with an LDL cholesterol below 1.8 mmol/l, using a higher dose statin. Which statin is chosen the same way: moderate-intensity statin therapy for adults 40 to 75 years of age with diabetes, high-intensity where there are diabetes-related complications, ASCVD or CVD risk factors, and in type 1 diabetes statin therapy for primary prevention in adults older than 40 years, or with diabetes for more than 10 years, or with established nephropathy. Start with atorvastatin 20 mg. The two intensities are set by their LDL-C lowering effect. High intensity lowers LDL-C by 50% or more: atorvastatin 40-80mg or rosuvastatin 20-40mg. Moderate intensity lowers it 30% to 49%: atorvastatin 10-20mg, rosuvastatin 5-10mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg or fluvastatin XL, extended release, 80mg, the last three not being in the MoH Drug Formulary. Atorvastatin 20 mg is therefore a moderate intensity dose. Where the targets are not reached on maximally-tolerated doses of statins, combination therapy with an agent such as ezetimibe may be considered.